作者: Emanuele Di Angelantonio ; Biomedical Excellence for Safer Transfusion Collaborative (Best) Investigators ; Marc Germain ; Katja van den Hurk ; Mindy Goldman ; Whitney R Steele ; Ralph R Vassallo ; Sheila F O'Brien

BACKGROUND:

We compared donor and general population demographics over time to provide insight into current donation patterns and the future adequacy of the blood supply.

STUDY DESIGN AND METHODS:

Seventeen blood center members of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative from 12 countries provided the number of donors and people in the general population by demographic category for 2001 and 2011, changes in age criteria, and percentage of first‐time donors. We calculated the median age of donors and the general population and determined the percentage of each group in age and sex cohorts.

RESULTS:

Age criteria vary, with upper limits recently liberalized in several countries. In 2011, the percentage of first‐time donors ranged from 10% to 41%. The median age of the donor and general population increased from 2001 to 2011 in most countries, as did the percentage of the general population over 60. The youngest donor cohort is overrepresented to a variable degree; this tendency increased over time. Although still underrepresented, older donors contributed more in 2011. A large middle‐aged cohort is aging at a rate exceeding the progression of time, while 25‐ to 45‐year‐olds are relatively underrepresented.

CONCLUSIONS:

All participating countries are experiencing aging of their general population. Donor demographics differ substantially between countries; this can be only partly explained by population demographics and age criteria. Many countries have an aging middle‐aged donor and population cohort and are increasingly relying on their youngest donors to contribute disproportionately to the blood supply.

2017-07-01·TRANSFUSION

Trends in age and red blood cell donation habits among several racial/ethnic minority groups in the United States.

Article

作者: Sayers, Merlyn ; Germain, Marc ; Delaney, Meghan ; Yazer, Mark H ; Shaz, Beth H ; Vassallo, Ralph ; Karafin, Matthew S ; van de Watering, Leo

BACKGROUND:

To meet the needs of a diverse patient population, an adequate supply of red blood cells (RBCs) from ethnic/racial minority donors is essential. We previously described the 10-year changes in minority blood donation in the United States. This study describes donation patterns by donor status, age, and race/ethnicity.

STUDY DESIGN AND METHODS:

Data on the age and the number of unique black/African American, Hispanic/Latino, Asian, and white RBC donors were obtained from eight US blood collectors for 2006, 2009, 2012, and 2015. Donors self-identified their race/ethnicity. First-time (FT) and repeat (R) donors were analyzed separately.

RESULTS:

Overall, for both FT and R donor groups, whites constituted the majority of unique donors (FT 66.7% and R 82.7%) and also donated the greatest proportion of RBC units (FT 66.6% and R 83.8%). Donors less than 20 years old comprised the greatest proportion of FT donors for all racial/ethnic groups (39.2%) and had the highest mean number of RBC donations per donor (1.12) among FT donors. Conversely, R donors less than 20 years old had some of the lowest mean number of RBC donations per donor (1.55) among R donors, whereas R donors at least 60 years old had the highest mean (1.88). Year by year, the percentage of FT donors who were less than 20 years old increased for all race/ethnicities. For R donors, whites were more frequently older, while Hispanics/Latinos and Asians were younger.

CONCLUSIONS:

Greater efforts to convert FT donors less than 20 years into R donors should be undertaken to ensure the continued diversity of the blood supply.

2017-05-01·TRANSFUSION

Trends in US minority red blood cell unit donations.

Article

作者: Germain, Marc ; Delaney, Meghan ; Yazer, Mark H ; Shaz, Beth ; Vassallo, Ralph ; Karafin, Matthew S ; Ziman, Alyssa ; Sayers, Merlyn

BACKGROUND:

To provide the appropriately diverse blood supply necessary to support alloimmunized and chronically transfused patients, minority donation recruitment programs have been implemented. This study investigated temporal changes in minority red blood cell (RBC) donation patterns in the United States.

STUDY DESIGN AND METHODS:

Data on donor race and ethnicity from 2006 through 2015, including the number of unique donors, collections, RBCs successfully donated, and average annual number of RBC donations per donor (donor fraction), were collected from eight US blood collectors. Minority donors were stratified into the following groups: Asian, black or African American, Hispanic or Latino, Native Indian or Alaska Native, Native Hawaiian or other Pacific Islander, white, multiracial/other, and no answer/not sure.

RESULTS:

Over the 10-year period, white donors annually constituted the majority of unique donors (range, 70.7%-73.9%), had the greatest proportion of collections (range, 76.1%-79.8%), and donated the greatest proportion of RBC units (range, 76.3%-80.2%). These donors also had the highest annual donor fraction (range, 1.82-1.91 units per donor). Black or African American donors annually constituted between 4.9 and 5.2% of all donors during the study period and donated between 4.0 and 4.3% of all RBC units. Linear regression analysis revealed decreasing numbers of donors, collections, and donated RBC units from white donors over time.

CONCLUSION:

Although the US population has diversified, and minority recruitment programs have been implemented, white donors constitute the majority of RBC donors and donations. Focused and effective efforts are needed to increase the proportion of minority donors.

项与 Vitalant 相关的新闻（医药）

2024-09-09

·PRNewswire

Blood Donations Are Needed for Those Battling Cancer

New virtual blood drive program helps Vitalant blood donors multiply their impact SCOTTSDALE, Ariz., Sept. 9, 2024 /PRNewswire/ -- More than 25% of the U.S. blood supply is needed by patients battling cancer. This September, during Childhood Cancer Awareness Month and Blood Cancer Awareness Month, nonprofit Vitalant urges all eligible donors to help maintain a robust blood supply for patients who need transfusions by giving blood. Blood and platelet transfusions from healthy blood donors can help replace the blood cells destroyed by cancer and its treatment. In the U.S., leukemia is the most common type of blood cancer among those under age 20. Continue Reading Tanner Bradtke on his first day of first grade. Six-year-old Tanner Bradtke has been sidelined from soccer since he was diagnosed with leukemia in April. The first-grader has been in and out of the hospital four times and received eight transfusions over the course of his treatment. "We notice a big difference when Tanner gets a blood transfusion," said Samantha Bradtke, Tanner's mom. "He gets his color back and has a better appetite! Tanner also tells us he doesn't feel as wobbly. So, we know he's not feeling so dizzy. Platelet transfusions also help prevent his gums from bleeding, which protects him from getting sick. It's hard to imagine what would happen if these blood donations were not readily available." (Read more about Tanner's battle.) Host a Virtual Blood Drive Giving blood or platelets is just one way to help patients like Tanner. Hosting a blood drive can empower a community to save lives. Creating a virtual blood drive allows friends and family all over the country to rally around the cause. Starting a virtual blood drive is simple: visit vbd.vitalant.org and within minutes you can start spreading the word, saving lives and watching the impact of your efforts add up. Give Blood Blood donors are needed every day to replenish what a patient in the U.S. needs every two seconds. Most people are eligible to donate.. Review eligibility requirements and make an appointment to give by visiting vitalant.org, download and use the Vitalant blood donor app or call 877-25-VITAL (877-258-4825). About Vitalant Vitalant (Vye-TAL-ent) is one of the nation's largest nonprofit blood and biotherapies healthcare organizations, providing hospitals and patients across the U.S. a safe blood supply, specialized laboratory services, transfusion medicine expertise and world-renowned research. Individuals generously donating blood, volunteering and giving financially are essential to our lifesaving mission. Learn more at vitalant.org. Vitalant Contact: 480-675-5413 SOURCE Vitalant

2024-05-17

·FiercePharma

From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)

None This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing. They also discuss the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Additionally, they talk about Germfree’s recent asset acquisition from Orgenesis, which will allow the company to expand its mission of decentralized manufacturing. To learn more about the topics in this episode: Fulfilling the promise of cell & gene therapies through manufacturing (Part I) With new partnership, Galapagos takes decentralized CAR-T manufacturing quest nationwide Catalent opens cell therapy production site at Belgian 'center of excellence' After recent troubles, Catalent expands its biologics services platform

细胞疗法并购基因疗法

2024-05-07

·BioSpace

Excellos Announces Acceleration of Commercialization, New CEO

New investment funds expansion of commercial team SAN DIEGO--(BUSINESS WIRE)-- Excellos Inc., a cell therapy contract and development manufacturing organization (CDMO), today announced it had taken additional investment to accelerate commercialization efforts. As part of the change new CEO Thomas VanCott, Ph.D., will step in to lead the company, while David Wellis, Ph.D., will transfer to Head of Strategic Partnerships. Dr. VanCott previously held the role of Chief Scientific Officer at Combined Therapeutics, Inc. and prior was Chief Technology & Strategy Officer of Catalent Cell and Gene Therapy. Excellos declined to disclose the origin of the multimillion-dollar investment, but according to CEO Dr. VanCott, it was provided by one of the current investors who expressed enthusiasm for Excellos' expansion of the business team. “This investment allows Excellos to expand business outreach. It resolves one of the main scaling challenges at Excellos where the CEO role was hands-on for both operations and business development” stated Dr. VanCott. “Dr. Wellis will now focus on business development, and I will lead overall operations.” According to Dr. Wellis, “2024 is shaping up to be an exciting year of significant growth for Excellos and there is nothing more important than tight, robust operations. We have built a magnificent facility, run by a highly skilled team, that large pharma and biotechs can trust to work with on cell therapies in clinical trials, as well as FDA-approved commercial products.” Excellos announced previously this year a strategic partnership and investment from Vitalant that focused on extending Excellos’ collection network and the donor characterization technology platform, Excellos 360. “With the technology investment earlier this year, these new resources and changes to business operations are a natural progression” said Dr. VanCott. “Excellos is now positioned to further assist our cell therapy and development partners with well-characterized metabolic and effector function profiles from highly-customized donors.” About Excellos Excellos provides custom cGMP services to develop and manufacture cell therapies. Featuring proprietary cell characterization technologies, Excellos reduces variabilities in clinical responses and increases the probability of successful outcomes. Current applications support TIL-based therapies, autologous and allogeneic CAR-T/NK therapies and TCR therapies. Customized services include donor recruitment, cell isolation, transduction, expansion and scale up GMP production. Learn more at . View source version on businesswire.com: Contacts Excellos Media Contact Marianne Woodard Press and Project Specialist customerservice@brainspores.com +1 408-313-8583 Source: Excellos Inc. View this news release online at:

高管变更细胞疗法

100 项与 Vitalant 相关的药物交易

登录后查看更多信息

100 项与 Vitalant 相关的转化医学

登录后查看更多信息